MY008211A tablets matched placebo

DRUG2 trials

Sponsors

Wuhan Createrna Science and Technology Co., Ltd

Conditions

IgA Nephropathy (IgAN)Paroxysmal Nocturnal Hemoglobinuria

Phase 1

A Study of Multiple Ascending Doses MY008211A in Healthy Adults

CompletedNCT05828472

Wuhan Createrna Science and Technology Co., LtdParoxysmal Nocturnal Hemoglobinuria

Start: 2023-01-10End: 2023-06-30Updated: 2023-09-08

Phase 2

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

Not yet recruitingNCT06687174

Wuhan Createrna Science and Technology Co., LtdIgA Nephropathy (IgAN)

Start: 2024-12-31End: 2028-01-31Target: 72Updated: 2024-11-18